Literature DB >> 19855252

Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients.

Aylin Yilmaz1, Victoria Watson, Laura Else, Magnus Gisslèn.   

Abstract

In order to assess the penetration of maraviroc to the central nervous system, we measured maraviroc concentrations in cerebrospinal fluid (CSF) and plasma. Concentrations were determined by liquid chromatography tandem mass spectrometry (lower limit of quantitation 1.25 ng/ml) in seven paired CSF and plasma samples. The median plasma maraviroc concentration was 94.9 ng/ml (range 21.4-478.0) and the median CSF concentration was 3.63 ng/ml (range 1.83-12.2). CSF samples exceeded the median EC90 for maraviroc (0.57 ng/ml) by at least three-fold. The CSF levels of maraviroc found in this study likely contribute to viral suppression in the CSF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19855252     DOI: 10.1097/QAD.0b013e328333ae0e

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  25 in total

1.  Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration.

Authors:  David Croteau; Brookie M Best; Scott Letendre; Steven S Rossi; Ronald J Ellis; David B Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; John Allen McCutchan; Susan Morgello; Igor Grant
Journal:  AIDS       Date:  2012-04-24       Impact factor: 4.177

2.  Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations.

Authors:  Eric H Decloedt; Bernd Rosenkranz; Gary Maartens; John Joska
Journal:  Clin Pharmacokinet       Date:  2015-06       Impact factor: 6.447

Review 3.  Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art.

Authors:  Luisa Fiandra; Amedeo Capetti; Luca Sorrentino; Fabio Corsi
Journal:  J Neuroimmune Pharmacol       Date:  2016-11-10       Impact factor: 4.147

Review 4.  HIV-associated neurological disorders: a guide to pharmacotherapy.

Authors:  Ik L Tan; Justin C McArthur
Journal:  CNS Drugs       Date:  2012-02-01       Impact factor: 5.749

Review 5.  HIV, antiretroviral therapies, and the brain.

Authors:  Kevin J Liner; Michelle J Ro; Kevin R Robertson
Journal:  Curr HIV/AIDS Rep       Date:  2010-05       Impact factor: 5.071

Review 6.  CSF penetration by antiretroviral drugs.

Authors:  Christine Eisfeld; Doris Reichelt; Stefan Evers; Ingo Husstedt
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

Review 7.  CCR5 blockade for neuroinflammatory diseases--beyond control of HIV.

Authors:  Guillaume Martin-Blondel; David Brassat; Jan Bauer; Hans Lassmann; Roland S Liblau
Journal:  Nat Rev Neurol       Date:  2016-01-18       Impact factor: 42.937

8.  CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.

Authors:  T J Barber; A Imaz; M Boffito; J Niubó; A Pozniak; R Fortuny; J Alonso; N Davies; S Mandalia; D Podzamczer; B Gazzard
Journal:  J Neurovirol       Date:  2017-12-26       Impact factor: 2.643

9.  Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.

Authors:  Babafemi Taiwo; Edward P Acosta; Patrick Ryscavage; Baiba Berzins; Darlene Lu; Jay Lalezari; Jose Castro; Oluwatoyin Adeyemi; Daniel R Kuritzkes; Joseph J Eron; Athe Tsibris; Susan Swindells
Journal:  J Acquir Immune Defic Syndr       Date:  2013-10-01       Impact factor: 3.731

Review 10.  Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder.

Authors:  Scott Letendre
Journal:  Top Antivir Med       Date:  2011-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.